Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MediSapiens to Provide Bayer HealthCare Pharmaceuticals With a New Cloud Computing Application to Analyze and Visualize Multi



   MediSapiens to Provide Bayer HealthCare Pharmaceuticals With a New Cloud
Computing Application to Analyze and Visualize Multi-Dimensional Genomics Data

PR Newswire

HELSINKI, November 5, 2012

HELSINKI, November 5, 2012 /PRNewswire/ --

MediSapiens Ltd, a Finnish company developing web-based data applications for
the pharmaceutical industry, today announced that Bayer HealthCare
Pharmaceuticals has purchased a new software solution developed by
MediSapiens. The software, called OncoGenomics Explorer will provide Bayer
HealthCare Pharmaceuticals with a centralized access to unified global
genomics data for utilization across the entire research organization from
target discovery to drug repositioning.

     (Logo: http://photos.prnewswire.com/prnh/20121105/573244 )

"Big Data, a term invented for a collection of data sets so large and complex
that it becomes difficult to process using on-hand database management tools
is quickly becoming increasingly important in pharmaceutical research. Until
now, the lack of software tools that can be adapted to various research
environments has limited the full-scale use of this enormous reservoir of
available data.  OncoGenomics Explorer is our answer to this demand," says
Tommi Pisto, CEO of MediSapiens Ltd.

About MediSapiens

MediSapiens is a bioinformatics company developing inspiring web applications
for genomics researchers, pharmaceutical industry and personalized medicine.
MediSapiens has unique know-how in developing software solutions for
integration of both molecular and clinical data from preclinical models to
interpreting comprehensive molecular profiles of individual cancer patients in
clinical settings. Based on the world's largest unified gene expression
database, MediSapiens platform extends into highly tailored solutions to meet
the exact needs of various demanding research environments.

For more information visit http://www.medisapiens.com or email
contact@medisapiens.com

Media Contact

Tommi Pisto, CEO, Co-Founder
MediSapiens Ltd
Tukholmankatu 8 A
00290 Helsinki
Finland
Phone: +358-50-3631848
tommi.pisto@medisapiens.com

SOURCE MediSapiens
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement